Microbot Medical receives first Japanese patent for LIBERTY - The Robot Report

Microbot Medical, developer of the LIBERTY Endovascular Robotic System, has received its first Japanese patent covering the core technology of its compact robotic device designed to drive and manipulate elongate surgical tools. This milestone follows recent patents granted in the U.S., China, and Israel, as well as FDA 510(k) clearance in September. The company aims to expand beyond its initial focus on the U.S. market into strategically important regions like Japan, leveraging FDA clearance to potentially expedite local regulatory approvals and adoption. The LIBERTY system is designed to enhance precision, safety, and efficiency in neurovascular, cardiovascular, and peripheral vascular procedures through remote-controlled, single-use robotic technology. Microbot highlights that LIBERTY’s compact design could reduce procedure costs and improve care quality. Additionally, a recently granted patent for a modular robotic surgical system may enable adapting LIBERTY for a broader range of endovascular applications. To support ongoing development, commercialization, and regulatory efforts, Microbot plans to raise up